US FDA defines small number of animals for minor use designation
This article was originally published in SRA
The US Food and Drug Administration has issued a final rule defining what constitutes a “small number of animals” under the Minor Use and Minor Species Animal Health Act. The MUMS act offers incentives to pharma companies wanting to develop drugs for minor species and for uncommon diseases in major species1,2.
You may also be interested in...
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.